Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 TNFalpha therapy in psoriatic arthritis and psoriasis.

× No keyword cloud information.

55 in total

Review 1. Psoriatic arthritis.

Authors: J M Moll; V Wright
Journal: Semin Arthritis Rheum Date: 1973 Impact factor: 5.532

2. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors.

Authors: D R Bertolini; G E Nedwin; T S Bringman; D D Smith; G R Mundy
Journal: Nature Date: 1986 Feb 6-12 Impact factor: 49.962

3. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey.

Authors: G Krueger; J Koo; M Lebwohl; A Menter; R S Stern; T Rolstad
Journal: Arch Dermatol Date: 2001-03

4. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis.

Authors: A Y Goedkoop; M C Kraan; M B M Teunissen; D I Picavet; M A de Rie; J D Bos; P P Tak
Journal: Ann Rheum Dis Date: 2004-07 Impact factor: 19.103

5. A randomized trial of etanercept as monotherapy for psoriasis.

Authors: Alice B Gottlieb; Robert T Matheson; Nicholas Lowe; Gerald G Krueger; Sewon Kang; Bernard S Goffe; Anthony A Gaspari; Mark Ling; Gerald D Weinstein; Anjuli Nayak; Kenneth B Gordon; Ralph Zitnik
Journal: Arch Dermatol Date: 2003-12

6. Psoriatic arthritis in psoriatic patients.

Authors: R Scarpa; P Oriente; A Pucino; M Torella; L Vignone; A Riccio; C Biondi Oriente
Journal: Br J Rheumatol Date: 1984-11

7. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

Authors: Daniel E Furst; Michael H Schiff; Roy M Fleischmann; Vibeke Strand; Charles A Birbara; Daniele Compagnone; Steven A Fischkoff; Elliot K Chartash
Journal: J Rheumatol Date: 2003-12 Impact factor: 4.666

8. Etanercept as monotherapy in patients with psoriasis.

Authors: Craig L Leonardi; Jerold L Powers; Robert T Matheson; Bernard S Goffe; Ralph Zitnik; Andrea Wang; Alice B Gottlieb
Journal: N Engl J Med Date: 2003-11-20 Impact factor: 91.245

9. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts.

Authors: J M Dayer; B Beutler; A Cerami
Journal: J Exp Med Date: 1985-12-01 Impact factor: 14.307

10. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage.

Authors: J Saklatvala
Journal: Nature Date: 1986 Aug 7-13 Impact factor: 49.962

26 in total

Review 1. Paradoxical inflammation induced by anti-TNF agents in patients with IBD.

Authors: Isabelle Cleynen; Séverine Vermeire
Journal: Nat Rev Gastroenterol Hepatol Date: 2012-07-03 Impact factor: 46.802

2. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists.

Authors: S Kary; M Worm; H Audring; D Huscher; M Renelt; H Sörensen; E Ständer; U Maass; H Lee; W Sterry; G-R Burmester
Journal: Ann Rheum Dis Date: 2005-09-08 Impact factor: 19.103

3. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.

Authors: A Kavanaugh; G G Krueger; A Beutler; C Guzzo; B Zhou; L T Dooley; P J Mease; D D Gladman; K de Vlam; P P Geusens; C Birbara; D G Halter; C Antoni
Journal: Ann Rheum Dis Date: 2006-11-17 Impact factor: 19.103

Review 4. Genetics of susceptibility and treatment response in psoriatic arthritis.

Authors: Darren D O'Rielly; Proton Rahman
Journal: Nat Rev Rheumatol Date: 2011-11-08 Impact factor: 20.543

5. Psoriasis after treatment of juvenile idiopathic arthritis with etanercept.

Authors: R Peek; R Scott-Jupp; H Strike; J Clinch; A V Ramanan
Journal: Ann Rheum Dis Date: 2006-09 Impact factor: 19.103

6. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment.

Authors: A W R van Kuijk; P Reinders-Blankert; T J M Smeets; B A C Dijkmans; P P Tak
Journal: Ann Rheum Dis Date: 2006-05-25 Impact factor: 19.103

10. [First manifestation of psoriasis vulgaris in tumor necrosis factor receptor-associated periodic syndrome during treatment with etanercept].

Authors: S Boms; T Sehr; U Jappe; A Enk
Journal: Hautarzt Date: 2008-08 Impact factor: 0.751

TNFalpha therapy in psoriatic arthritis and psoriasis.